更新于：2024-12-16
Cefdinir
头孢地尼
更新于：2024-12-16
概要
基本信息
简介头孢地尼作为青霉素结合蛋白 (PBP) 抑制剂和细胞壁抑制剂，以商品名 Omnicef 销售，适用于敏感菌引起的感染的治疗和预防。 头孢地尼通过抑制引起感染的细菌（包括链球菌、葡萄球菌和流感嗜血杆菌）的生长和繁殖起作用。 它在多个国家/地区获得批准，包括美国、中国、日本和韩国。 Omnicef 有胶囊剂或口服混悬剂两种形式，通常根据感染的严重程度每天服用一次或两次。 值得注意的是，应该仅将这种药物用于治疗或预防细菌感染，因为过度使用或误用会导致耐药细菌的产生。 |
药物类型 小分子化药 |
别名 Cefdinir (JP17/USP/INN)、Cefzon Capsule、CFDN + [19] |
靶点 |
作用机制 PBPs抑制剂(细菌青霉素结合蛋白家族抑制剂)、细胞壁抑制剂 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构
分子式C14H13N5O5S2 |
InChIKeyRTXOFQZKPXMALH-GHXIOONMSA-N |
CAS号91832-40-5 |
关联
82
项与 头孢地尼 相关的临床试验Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing
中国健康受试者空腹和餐后口服STBN的随机、开放、两序列、两周期、双交叉设计的生物等效性试验
头孢地尼干混悬剂在健康受试者中单中心、随机、开放、两制剂、单次给药、两周期、双交叉空腹/餐后生物等效性试验研究方案
100 项与 头孢地尼 相关的临床结果
登录后查看更多信息
100 项与 头孢地尼 相关的转化医学
登录后查看更多信息
100 项与 头孢地尼 相关的专利（医药）
登录后查看更多信息
507
项与 头孢地尼 相关的文献（医药）2024-12-01ARCHIVES OF MICROBIOLOGY
Affinity of cefditoren for penicillin-binding proteins in bacteria and its relationship with antibiotic sensitivity
Article
作者: Deng, Yi ; Qi, Yixin ; Ma, Lingman ; Shi, Qixue ; Xu, Liang ; Zhou, Changlin
Penicillin-binding proteins (PBPs) are the targets of β-lactam antibiotics; however, changes in the affinity of PBPs for beta-lactam antibiotics often affect the susceptibility of bacteria to antibiotics. The purpose of this study was to elucidate the mechanism by which cefditoren, an oral third-generation cephalosporin, binds PBPs. The minimal inhibitory concentration (MIC), bactericidal curves, and inhibition zone comparisons were assessed to evaluate the antibacterial activity of cefditoren. PBP1A and PBP2X proteins from Streptococcus pneumoniae were purified, and their ability to bind to cefditoren was investigated via microscale thermophoresis. The Kd of cefditoren toward PBP1A was 0.005 ± 0.004 µM, which was lower than those of other cephalosporins (cefcapene, cefixime and cefdinir). In contrast, the Kd of cefditoren toward PBP2X of S. pneumoniae was 9.70 ± 8.24 µM, which was lower than that of cefixime but higher than those of cefcapene and cefdinir. Additionally, the biotinylated ampicillin (BIO-AMP) method was employed to evaluate the affinity of cefditoren toward PBPs of Haemophilus influenzae, and the results demonstrated that cefditoren and PBP3A/B had the lowest IC50 values (0.060 ± 0.002 µM). These findings indicate that cefditoren has a strong affinity for PBP1A of H. influenzae. Cefditoren has a high affinity toward the PBP1As of S. pneumoniae and PBP1A and PBP3A/B of H. influenzae, which may contribute to the effective antibacterial effects of cefditoren against clinical strains and its low propensity for inducing resistance. The data presented in this article help elucidate the mechanism by which cefditoren, an oral third-generation cephalosporin, binds to PBPs and provide theoretical support for the wider use of cefditoren as an antibiotic therapy.
2024-12-01INTERNATIONAL JOURNAL OF PHARMACEUTICS
Formulation and optimization of surfactant-modified chitosan nanoparticles loaded with cefdinir for novel topical drug delivery: Elevating wound healing efficacy with enhanced antibacterial properties
Article
作者: Badie, Merna A. ; El-Nabarawi, Mohamed A. ; Badie, Merna A ; El-Nabarawi, Mohamed A ; Badawi, Noha M. ; Badawi, Noha M ; Teaima, Mahmoud H. ; Teaima, Mahmoud H
Burn wounds remain a significant global health concern, frequently exacerbated by bacterial infections that hinder healing and raise morbidity rates. Cefdinir, a third-generation cephalosporin antibiotic, is used to treat various conditions, but it has limitations such as low water solubility, limited bioavailability, and a short biological half-life. This study aimed to fabricate and optimize novel surfactant-based Cefdinir-loaded chitosan nanoparticles (CFD-CSNPs) for enhancing topical CFD delivery and efficacy in burn healing. Box-Behnken Design (BBD) was employed to develop optimized CFD-CSNPs using Design Expert® software, where the independent factors were chitosan concentration, chitosan: sodium tripolyphosphate ratio, pH, and surfactant type. Particle size PS, zeta potential ZP, Polydispersity index PDI, and entrapment efficiency EE% were evaluated as dependent factors. CFD-CSNPs were produced using the ionic gelation method. The optimized formula was determined and then examined for further in vitro and in vivo assessments. The optimized CFD-CSNPs exhibited acceptable PS, PDI, and ZP values. The EE% of CFD from CSNPs reached 57.89 % ± 1.66. TEM analysis revealed spherical morphology. In vitro release studies demonstrated a biphasic release profile up to (75.5 % ± 3.8) over 48 hrs. The optimized CFD-CSNPs showed improved antimicrobial efficacy against the tested microorganisms, exhibiting superior performance for both biofilm prevention and eradication. Enhanced wound healing activity was achieved by the optimized CFD-CSNPs in both in vitro and in vivo studies as confirmed by scratch wound assay and skin burn mice model. The current study advocates the efficacy of the innovative topical application of CFD-CSNPs for wound healing purposes and treatment of wound infections.
2024-11-01JOURNAL OF ARTHROPLASTY
Rates of Extended Oral Antibiotic Prophylaxis After Primary Total Knee Arthroplasty Among High-Risk and Standard-Risk Patients: 2009 to 2022
Article
作者: Premkumar, Ajay ; Wilson, Jacob M. ; Wilson, Jacob M ; Pisharody, Vivek A ; Fuqua, Andrew ; Pisharody, Vivek A. ; Erens, Greg ; Ayeni, Ayomide
INTRODUCTION:
Recent evidence suggests extended courses of oral antibiotics (EOA) after total hip (THA) and knee (TKA) arthroplasty may reduce the risk of periprosthetic joint infection (PJI) in high-risk patients. EOA rates after THA have risen significantly. However, there is a lack of epidemiologic data on EOA prophylaxis following TKA. Therefore, we investigated national trends in EOA prophylaxis for primary TKA and whether these rates were reflective of changes in patient risk or prescribing practices.
METHODS:
Adult patients undergoing TKA between 2009 and 2022 were identified in a national insurance claims database (Merative Marketscan). EOA was defined as a 7-14 day course of a first-generation cephalosporin, cefdinir, clindamycin, doxycycline, or trimethoprim-sulfamethoxazole filled between 5 days preoperatively to 3 days postoperatively. Annual EOA rates were calculated and stratified by preoperative PJI risk. Multivariable logistic regression was used to explore whether rates reflected changing patient characteristics. Future rates were predicted with time-series forecasting.
RESULTS:
We identified 712,212 eligible TKA cases. EOA rates rose from 0.91% in 2009 to 7.95% in 2022. Rates increased by 686% among standard-risk patients and 786% among high-risk patients. Logistic regression models using patient comorbidities could not account for changes in EOA rates. EOA rates were projected to rise to 18.3% (CF: 7.5-29.0%) by 2030.
CONCLUSION:
Rates of EOA prophylaxis after TKA rose significantly from 2009 to 2022. This trend could not be explained by changing patient characteristics, suggesting widespread changes in antibiotic prescribing practices, which may be reflective of recent studies favoring EOA use. There is a need for further high-quality research examining the safety, efficacy, and role of EOA prophylaxis in the primary TKA patient population.
100 项与 头孢地尼 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 支气管炎 | 日本 | 2017-04-27 | |
| 膀胱炎 | 日本 | 2017-04-27 | |
| 中耳炎 | 日本 | 2017-04-27 | |
| 细菌性肺炎 | 日本 | 2017-04-27 | |
| 鼻窦炎 | 日本 | 2017-04-27 | |
| 细菌性皮肤疾病 | 日本 | 2017-04-27 | |
| 急性上颌窦炎 | 美国 | 1997-12-04 | |
| 细菌性中耳炎 | 美国 | 1997-12-04 | |
| 慢性支气管炎 | 美国 | 1997-12-04 | |
| 社区获得性肺炎 | 美国 | 1997-12-04 | |
| 简单的皮肤和皮肤结构感染(uSSSI) | 美国 | 1997-12-04 | |
| 咽炎 | 美国 | 1997-12-04 | |
| 扁桃体炎 | 美国 | 1997-12-04 | |
| 细菌感染 | 日本 | 1991-10-04 | |
| 革兰氏阴性菌感染 | - | - | 1991-01-01 |
| 革兰氏阳性细菌感染 | - | - | 1991-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 急性中耳炎 | 临床3期 | 美国 | 2002-07-01 | |
| 急性中耳炎 | 临床3期 | 智利 | 2002-07-01 | |
| 急性中耳炎 | 临床3期 | 哥斯达黎加 | 2002-07-01 | |
| 急性中耳炎 | 临床3期 | 多米尼加共和国 | 2002-07-01 | |
| 急性中耳炎 | 临床3期 | 危地马拉 | 2002-07-01 | |
| 急性中耳炎 | 临床3期 | 以色列 | 2002-07-01 | |
| 急性中耳炎 | 临床3期 | 巴拿马 | 2002-07-01 | |
| 意外伤害 | 临床1期 | 中国 | 2013-03-24 | |
| 急性支气管炎 | 临床1期 | 中国 | 2013-03-24 | |
| 附件炎 | 临床1期 | 中国 | 2013-03-24 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 385 | aminopenicillin+clavulanate+amoxicillin trihydrate+Cefdinir (Short Course) | 鏇鏇醖顧艱顧築壓鑰願(築觸繭網遞衊簾鑰廠壓): Pr (Higher DOOR in Short-Course) = 0.69 (95% CI, 0.63 ~ 0.75), P-Value = <0.001 更多 | - | 2021-02-03 | ||
(Standard Course) | |||||||
临床1期 | - | 32 | (Cefdinir (Test)) | 顧醖鑰鏇鹽鬱遞範淵鏇(鑰範壓獵艱構獵範齋衊) = 積鏇簾範觸繭蓋範襯鑰 廠壓範鑰觸壓艱夢鹹窪 (壓顧夢襯繭蓋選築範淵, 鏇觸衊鹹窪範齋憲廠廠 ~ 艱憲鑰糧製積遞簾齋壓) 更多 | - | 2009-07-21 | |
(Omnicef® (Reference)) | 顧醖鑰鏇鹽鬱遞範淵鏇(鑰範壓獵艱構獵範齋衊) = 壓獵糧淵蓋願獵壓範襯 廠壓範鑰觸壓艱夢鹹窪 (壓顧夢襯繭蓋選築範淵, 簾獵窪艱鏇壓鏇糧構壓 ~ 夢選遞齋願餘艱顧願獵) 更多 | ||||||
临床1期 | - | 32 | (Cefdinir (Test)) | 糧積蓋築餘顧網鏇遞鏇(積簾觸觸壓願齋襯糧糧) = 鹽壓繭蓋夢鬱襯獵網鬱 獵簾製願選鹽艱獵範糧 (製顧積鬱膚膚鑰鬱願積, 夢觸餘獵鏇淵襯鹽襯醖 ~ 築壓醖糧憲夢選繭廠範) 更多 | - | 2009-07-21 | |
(Omnicef® (Reference)) | 糧積蓋築餘顧網鏇遞鏇(積簾觸觸壓願齋襯糧糧) = 餘餘窪範蓋顧憲鏇壓鏇 獵簾製願選鹽艱獵範糧 (製顧積鬱膚膚鑰鬱願積, 鏇蓋遞艱膚齋網憲簾積 ~ 齋夢簾鬱觸蓋淵築獵觸) 更多 | ||||||
临床1期 | - | 32 | (Cefdinir (Test)) | 獵鑰糧鏇餘糧夢鹽糧鑰(製範鹽鏇網餘顧顧壓窪) = 顧觸憲壓鏇鬱襯製餘廠 繭網網憲蓋淵憲襯憲醖 (衊製構糧鏇鹹顧廠構顧, 簾鏇衊願鹽壓鹽糧遞憲 ~ 鹹廠鑰窪膚鬱網窪製遞) 更多 | - | 2009-07-21 | |
(Omnicef® (Reference)) | 獵鑰糧鏇餘糧夢鹽糧鑰(製範鹽鏇網餘顧顧壓窪) = 夢衊獵簾獵簾糧製選繭 繭網網憲蓋淵憲襯憲醖 (衊製構糧鏇鹹顧廠構顧, 觸膚窪醖糧膚製製鏇淵 ~ 繭遞憲鬱獵壓夢艱範觸) 更多 | ||||||
临床1期 | - | 32 | (Cefdinir (Test)) | 衊糧窪鑰願觸觸淵範廠(襯醖窪夢繭簾糧鹽膚艱) = 鏇鏇齋鏇築築網願遞壓 選範築夢醖製壓鑰蓋淵 (獵範膚願餘窪顧構憲鏇, 鹹網願憲鹹觸積製廠網 ~ 鑰鹽獵鑰獵繭淵獵廠鹹) 更多 | - | 2009-07-21 | |
(Omnicef® (Reference)) | 衊糧窪鑰願觸觸淵範廠(襯醖窪夢繭簾糧鹽膚艱) = 鏇製簾鬱壓築網築鬱築 選範築夢醖製壓鑰蓋淵 (獵範膚願餘窪顧構憲鏇, 範觸鑰廠齋糧顧範選獵 ~ 壓構襯鹽簾獵憲艱觸鑰) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用